OncoMatch

OncoMatch/Clinical Trials/NCT07729579

An Open-Label, Two-Cohort, Pharmacokinetic Study in a Maximal Use Setting for Patients With Actinic Keratosis on the Upper Extremities or the Face

Is NCT07729579 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Investigational drug and Photodynamic therapy for actinic keratosis (ak).

Phase 1RecruitingSun Pharmaceutical Industries LimitedNCT07729579Data as of Sep 2026

Treatment: Investigational drug · Photodynamic therapyThe research study will evaluate how the body absorbs and reacts to reformulated Levulan Kerastick when applied to actinic keratosis lesions (AKs) on the skin of the forearms or face followed by photodynamic therapy (PDT), a treatment that uses application of blue light.

Check if I qualify

Eligibility summary

For patients with actinic keratosis.

This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.

US trial sites

  • J&S Studies · College Station, Texas

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07729579 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 85 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify